title: 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: L
authors.initials: L
authors.lastname: Cannella
authors.forename: M
authors.initials: M
authors.lastname: Santopietro
authors.forename: G
authors.initials: G
authors.lastname: Loglisci
authors.forename: V
authors.initials: V
authors.lastname: Federico
authors.forename: A
authors.initials: A
authors.lastname: Salaroli
authors.forename: M
authors.initials: M
authors.lastname: Nanni
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D007446:Chromosome Inversion / Q000235:genetics*; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine